Relative Quantification of Nε-(Carboxymethyl)lysine, Imidazolone A, and the Amadori Product in Glycated Lysozyme by MALDI-TOF Mass Spectrometry
- 7 December 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 51 (1) , 51-57
- https://doi.org/10.1021/jf020768y
Abstract
The nonenzymatic glycation of proteins by reducing sugars, also known as the Maillard reaction, has received increasing recognition from nutritional science and medical research. In this study, we applied matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) to perform relative and simultaneous quantification of the Amadori product, which is an early glycation product, and of N(epsilon)-(carboxymethyl)lysine and imidazolone A, two important advanced glycation end products. Therefore, native lysozyme was incubated with d-glucose for increasing periods of time (1, 4, 8, and 16 weeks) in phosphate-buffered saline pH 7.8 at 50 degrees C. After enzymatic digestion with endoproteinase Glu-C, the N-terminal peptide fragment (m/z 838; amino acid sequence KVFGRCE) and the C-terminal peptide fragment (m/z 1202; amino acid sequence VQAWIRGCRL) were used for relative quantification of the three Maillard products. Amadori product, N(epsilon)-(carboxymethyl)lysine, and imidazolone A were the main glycation products formed under these conditions. Their formation was dependent on glucose concentration and reaction time. The kinetics were similar to those obtained by competitive ELISA, an established method for quantification of N(epsilon)-(carboxymethyl)lysine and imidazolone A. Inhibition experiments showed that coincubation with N(alpha)-acetylargine suppressed formation of imidazolone A but not of the Amadori product or N(epsilon)-(carboxymethyl)lysine. The presence of N(alpha)-acetyllysine resulted in the inhibition of lysine modifications but in higher concentrations of imidazolone A. o-Phenylenediamine decreased the yield of the Amadori product and completely inhibited the formation of N(epsilon)-(carboxymethyl)lysine and imidazolone A. MALDI-TOF-MS proved to be a new analytical tool for the simultaneous, relative quantification of specific products of the Maillard reaction. For the first time, kinetic data of defined products on specific sites of glycated protein could be measured. This characterizes MALDI-TOF-MS as a valuable method for monitoring the Maillard reaction in the course of food processing.Keywords
This publication has 25 references indexed in Scilit:
- Accumulation of Advanced Glycation End Products Decreases Collagen Turnover by Bovine ChondrocytesExperimental Cell Research, 2001
- Formation Pathways for Lysine-Arginine Cross-links Derived from Hexoses and Pentoses by Maillard ProcessesJournal of Biological Chemistry, 2001
- Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Advanced glycation end products: a highly complex set of biologically relevant compounds detected by mass spectrometryJournal of Mass Spectrometry, 2001
- N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene ExpressionJournal of Biological Chemistry, 1999
- Reactivities of d-glucose and d-fructose during Glycation of Bovine Serum AlbuminJournal of Agricultural and Food Chemistry, 1999
- Functional Proteomics Analysis of Signal Transduction Pathways of the Platelet-Derived Growth Factor β ReceptorBiochemistry, 1999
- Activation of β1 Integrin Signaling Stimulates Tyrosine Phosphorylation of p190 and Membrane-protrusive Activities at InvadopodiaJournal of Biological Chemistry, 1998
- Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.Journal of Clinical Investigation, 1997
- ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGINGAnnual Review of Medicine, 1995